Financial reports
10-K/A
2023 FY
Annual report (amended)
12 Apr 24
10-K
2023 FY
Annual report
20 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
16 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
Current reports
8-K/A
Other Events
12 Apr 24
8-K
Other Events
9 Apr 24
8-K
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
20 Mar 24
8-K
Voting and Support Agreement
19 Mar 24
8-K
Entry into a Material Definitive Agreement
16 Feb 24
8-K
Entry into a Material Definitive Agreement
19 Jan 24
8-K
Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates
4 Jan 24
8-K
Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates
7 Nov 23
8-K
Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors
16 Oct 23
8-K
Fusion Pharmaceuticals Announces Second Quarter 2023 Financial Results and Clinical Program Updates
8 Aug 23
Registration and prospectus
S-8
Registration of securities for employees
20 Mar 24
424B5
Prospectus supplement for primary offering
19 Jan 24
S-3
Shelf registration
16 Jun 23
S-3
Shelf registration
16 Mar 23
S-8
Registration of securities for employees
16 Mar 23
S-8
Registration of securities for employees
17 Mar 22
S-3
Shelf registration
2 Jul 21
S-8
Registration of securities for employees
25 Mar 21
S-8
Registration of securities for employees
30 Jun 20
424B4
Prospectus supplement with pricing info
26 Jun 20
Proxies
PREM14A
Preliminary proxy related to merger
10 Apr 24
DFAN14A
Additional proxy materials by non-management
19 Mar 24
DEFA14A
Additional proxy soliciting materials
19 Mar 24
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEF 14A
Definitive proxy
27 Apr 21
Other
EFFECT
Notice of effectiveness
28 Jun 23
CORRESP
Correspondence with SEC
23 Jun 23
UPLOAD
Letter from SEC
23 Jun 23
EFFECT
Notice of effectiveness
24 Mar 23
CORRESP
Correspondence with SEC
21 Mar 23
UPLOAD
Letter from SEC
21 Mar 23
EFFECT
Notice of effectiveness
14 Jul 21
CORRESP
Correspondence with SEC
8 Jul 21
UPLOAD
Letter from SEC
8 Jul 21
SEC STAFF
SEC staff action: Order
29 Mar 21
Ownership
SC 13G/A
FEDERATED HERMES, INC.
8 Apr 24
SC 13D
FEDERATED HERMES, INC.
25 Mar 24
SC 13D/A
HealthCap VII, L.P.
20 Mar 24
SC 13D/A
HealthCap VII, L.P.
7 Mar 24
SC 13G/A
CANADA PENSION PLAN INVESTMENT BOARD
14 Feb 24
SC 13G/A
Avidity Partners Management LP
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G
PERCEPTIVE ADVISORS LLC
19 Jan 24
SC 13G/A
FEDERATED HERMES, INC.
18 Jan 24
4
Christopher P Leamon
5 Jan 24